Literature DB >> 18473399

Occult persistence and lymphotropism of hepatitis C virus infection.

Tram-Nq Pham, Tomasz-I Michalak.   

Abstract

Recent discovery of occult hepatitis C virus (HCV) infection persisting after spontaneous or antiviral therapy-induced resolution of hepatitis C was made possible by the introduction of nucleic acid amplification assays capable of detecting HCV RNA at sensitivities superseding those offered by clinical tests. Although individuals with this seemingly silent HCV infection are usually anti-HCV antibody reactive and have normal liver function tests, occult HCV infection has also been reported in anti-HCV-negative individuals with persistently elevated liver enzymes of unknown etiology. Studies have shown that HCV RNA can persist for years in serum, lymphomononuclear cells and liver in the absence of clinical symptoms, although histological evidence of a mild inflammatory liver injury can be occasionally encountered. Furthermore, while HCV RNA can be detected in circulating lymphoid cells in approximately 30% of cases, a short-term culture under stimulatory conditions augments HCV replication in these cells allowing detection of virus in otherwise HCV-negative cases. HCV infects different immune cell subsets, including CD4+ and CD8+ T lymphocytes, B cells and monocytes. Studies employing clonal sequencing and single-stranded conformational polymorphism analyses have revealed unique HCV variants residing in immune cells, further strengthening the notion of HCV lymphotropism. Overall, the data accumulated suggest that occult HCV infection is a common consequence of resolution of symptomatic hepatitis C and that examination of the cells of the immune system is an effective approach to diagnosis of HCV infection and its long-term persistence. Further work is required to fully realize pathogenic and epidemiological consequences of occult HCV persistence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473399      PMCID: PMC2710716          DOI: 10.3748/wjg.14.2789

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

Review 2.  Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences.

Authors:  Jason T Blackard; Nyingi Kemmer; Kenneth E Sherman
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

3.  Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment.

Authors:  Inmaculada Castillo; Elena Rodríguez-Iñigo; Juan Manuel López-Alcorocho; Margarita Pardo; Javier Bartolomé; Vicente Carreño
Journal:  Clin Infect Dis       Date:  2006-10-05       Impact factor: 9.079

4.  Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.

Authors:  Abdel-Rahman N Zekri; Waleed S Mohamed; Mohamed A Samra; Ghada M Sherif; Amal M R El-Shehaby; Manal H El-Sayed
Journal:  Transpl Immunol       Date:  2004-12       Impact factor: 1.708

Review 5.  Occult hepatitis C virus infection: a new form of hepatitis C.

Authors:  Vicente Carreño
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

6.  Estimating progression to cirrhosis in chronic hepatitis C virus infection.

Authors:  A J Freeman; G J Dore; M G Law; M Thorpe; J Von Overbeck; A R Lloyd; G Marinos; J M Kaldor
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

Authors:  Tram N Q Pham; Sonya A MacParland; Patricia M Mulrooney; Helen Cooksley; Nikolai V Naoumov; Tomasz I Michalak
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro.

Authors:  Sonya A MacParland; Tram N Q Pham; Shashi A Gujar; Tomasz I Michalak
Journal:  J Gen Virol       Date:  2006-12       Impact factor: 3.891

10.  Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection.

Authors:  T N Q Pham; P M Mulrooney-Cousins; S E Mercer; S A MacParland; M Inglot; M Zalewska; K Simon; T I Michalak
Journal:  J Viral Hepat       Date:  2007-08       Impact factor: 3.728

View more
  19 in total

1.  Investigation of residual hepatitis C virus in presumed recovered subjects.

Authors:  Kei Fujiwara; Robert D Allison; Richard Y Wang; Patricia Bare; Kentaro Matsuura; Cathy Schechterly; Krishna Murthy; Francesco M Marincola; Harvey J Alter
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

Review 2.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

Review 3.  Hepatitis viruses and non-Hodgkin's lymphoma: A review.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Rudragoud S Policegoudra; Hemant K Gogoi; Lokendra Singh
Journal:  World J Virol       Date:  2012-12-12

4.  Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system.

Authors:  Richard Y Wang; Patricia Bare; Valeria De Giorgi; Kentaro Matsuura; Kazi Abdus Salam; Teresa Grandinetti; Cathy Schechterly; Harvey J Alter
Journal:  Hepatology       Date:  2016-10-24       Impact factor: 17.425

5.  Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy.

Authors:  Paolo Conca; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

6.  Genetic characterization of hepatitis B virus in peripheral blood leukocytes: evidence for selection and compartmentalization of viral variants with the immune escape G145R mutation.

Authors:  Sibnarayan Datta; Rajesh Panigrahi; Avik Biswas; Partha K Chandra; Arup Banerjee; Pradip K Mahapatra; Chinmoy K Panda; Shekhar Chakrabarti; Sujit K Bhattacharya; Kuntal Biswas; Runu Chakravarty
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

7.  Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.

Authors:  Florian Douam; Louis-Marie Bobay; Guillemette Maurin; Judith Fresquet; Noémie Calland; Carine Maisse; Tony Durand; François-Loïc Cosset; Cyrille Féray; Dimitri Lavillette
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

8.  Occult HCV infection: an unexpected finding in a population unselected for hepatic disease.

Authors:  Laura De Marco; Anna Gillio-Tos; Valentina Fiano; Guglielmo Ronco; Vittorio Krogh; Domenico Palli; Salvatore Panico; Rosario Tumino; Paolo Vineis; Franco Merletti; Lorenzo Richiardi; Carlotta Sacerdote
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

Review 9.  Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).

Authors:  Giuseppe Sautto; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-11-08       Impact factor: 5.048

10.  Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease.

Authors:  Laura De Marco; Paola Manzini; Morena Trevisan; Anna Gillio-Tos; Franca Danielle; Cinzia Balloco; Alessandra Pizzi; Eleonora De Filippo; Sergio D'Antico; Beatrice Violante; Adriano Valfrè; Franco Curti; Franco Merletti; Lorenzo Richiardi
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.